SYNTARA LIMITED ORDINARY (SNT) Short Interest
SYNTARA LIMITED ORDINARY (ASX:SNT) had 0.00% of shares reported as short positions as of 26 June 2026, representing 6,920 shares. SYNTARA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
SNT
Syntara
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials f...